SCHEMBL7584830

SCHEMBL7584830

C=CCSc1ccccc1C(=O)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.47
AKR1C3 P42330 1/20 0.46
CYP1A2 P05177 2/20 0.44
MAPT P10636 3/20 0.43
GAA P10253 1/20 0.43
ALDH1A1 P00352 3/20 0.43
LMNA P02545 2/20 0.43
HPGD P15428 1/20 0.43
POLB P06746 3/20 0.42
CYP3A4 P08684 2/20 0.41
ICMT O60725 1/20 0.41
GMNN O75496 1/20 0.41
TRPA1 O75762 1/20 0.41
CYP2C9 P11712 1/20 0.41
TSHR P16473 1/20 0.41
NFKB1 P19838 1/20 0.41
CDK2 P24941 1/20 0.41
RECQL P46063 1/20 0.41
BLM P54132 1/20 0.41
HIF1A Q16665 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8983732 0.90 CYP1A2 (0.44) RAB9ACYP1A2MAPTGAAALDH1A1
SCHEMBL8983737 0.88 AKR1C3 (0.41) RAB9AAKR1C3CYP1A2MAPTGAA
Benzene SCHEMBL27474313 0.85 CYP1A2 (0.61) RAB9ACYP1A2MAPTGAAALDH1A1
SCHEMBL6248402 0.85 CYP1A2 (0.61) RAB9ACYP1A2MAPTGAAALDH1A1
SCHEMBL11756536 0.80 CYP1A2 (0.42) RAB9ACYP1A2MAPTALDH1A1LMNA
SCHEMBL11302203 0.80 RAB9A (0.50) RAB9AAKR1C3CYP1A2MAPTGAA
SCHEMBL1399545 0.80 SIRT1 (0.50) RAB9ACYP1A2MAPTGAAALDH1A1
SCHEMBL13784467 0.80 POLB (0.46) RAB9ACYP1A2MAPTGAAALDH1A1
SCHEMBL8376800 0.79 POLB (0.65) RAB9AAKR1C3MAPTGAAALDH1A1
SCHEMBL28423660 0.78 RAB9A (0.51) RAB9AAKR1C3CYP1A2MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109843853-B Composition and method for manufacturing device using the same 东洋合成工业株式会社 2022-09-20 CN disclosed
US-11142495-B2 Composition and method for manufacturing device using same TOYO GOSEI CO., LTD. (JP) 2021-10-12 US disclosed
US-20200048191-A1 COMPOSITION AND METHOD FOR MANUFACTURING DEVICE USING SAME TOYO GOSEI CO., LTD. (JP) 2020-02-13 US disclosed
EP-0934256-B1 PROCESS FOR THE PRODUCTION OF CYANOCINNAMAMIDES HONEYWELL INT INC (US) 2002-08-21 EP disclosed
US-5654465-A Process for the production of cyanocinnamamides ALLIEDSIGNAL INC. (US) 1997-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048191-A1 COMPOSITION AND METHOD FOR MANUFACTURING DEVICE USING SAME LBR, LMTK2, MMS19 RAB9A 1212/4885AKR1C3 3041/4885CYP1A2 4723/4885
US-11142495-B2 Composition and method for manufacturing device using same LBR, LMTK2, MMS19 RAB9A 1212/4885AKR1C3 3041/4885CYP1A2 4723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.